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FROM HEALTH-RELATED QOL TO UTILITY—
IS THERE A WAY?
Svensson K1, Szende A2, Ståhl E1, Lundbäck B3
1AstraZeneca R&D Lund, Sweden, Lund, Sweden; 2Medtap
International, Jisp, Netherlands; 3University Hospital, Umeå,
Sweden
OBJECTIVE: To predict utility values from health-related
quality of life (HRQL) assessments could, if possible, 
be a fruitful way to use HRQL assessments for health 
economic evaluations. With this in mind, we compared
values for SF-6D, an index derived from the domain
values of SF-36 by an algorithm from Brazier et al., 
with values from the EuroQol instrument, the EQ-5D
index, and the EQ-VAS (Visual Analog Scale).
METHODS: Data from two surveys of patients with res-
piratory disease were used in this comparison. The ﬁrst
data set was from 120 patients in the northern part of
Sweden with COPD, and the other dataset from 206
patients in Hungary suffering from asthma. Both surveys
covered patients with different severity of the disease. The
two datasets were analyzed separately. The EQ-VAS
values were rescaled from a range of 0–100 to a 0–1
range.
RESULTS: Results are consistent for the two different
data sets and shows an expected gradient for severity
groups in both cases. SF-6D has on the average slightly
lower values than EQ-5D but higher than EQ-VAS (Mean
for COPD: 0.74 vs 0.78 and 0.65; ASTHMA: 0.69 vs.
0.70 and 0.62). On the other hand, both EQ-5D and EQ-
VAS have larger variation with a substantial proportion
of patients reaching maximum or minimum achievable
values. Correlations between the different indices are
deceptively high because of extreme values (r for COPD:
0.75–0.69; ASTHMA: 0.70–0.49).
CONCLUSION: SF-6D shows a response pattern more
in line with intuitive expectation than EQ-5D and EQ-
VAS, which both seem to have a ceiling (and ﬂoor)
problem.
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OBJECTIVE: To understand disease burden, prognosis,
and survival, and estimate target patient populations for
treatment, knowing the prevalence of patients by their
clinical stage of disease (AJCC/UICC/TNM) is important.
However, such data is not readily available in the pub-
lished SEER (Surveillance, Epidemiology and End
Results) statistics. Moreover, the SEER deﬁnitions for
staging cancer into local, regional, and distant has
changed from 1973–98, and do not coincide with the
AJCC clinical stages of I, II, III, and IV. The latter has
also undergone ﬁve editions from 1978–1997. Colorectal
cancer is the third most common incident cancer in the
US, with good prognosis and survival if detected early.
We estimated the prevalence and survival of colorectal
cancer by clinical stage.
METHODS: From the August 2001 release of the SEER
database, there were 281,940 cases with a diagnosis of
colorectal cancer and complete follow-up through
December 31, 1998. The different staging systems of
AJCC, TNM, SEER 2000, SEER 1977, SEER Historic
Coding, and Dukes/Astler-Collins were summarized and
compared, showing the differences and the overlap in the
staging systems. Colorectal cancer cases diagnosed from
1988–1998 (n = 129,664) were recoded to the AJCC
coding system by SEER. In order to estimate age-adjusted
prevalence by stage for the year 2001, we calculated the
1998 age speciﬁc prevalence. This latter ﬁgure was stan-
dardized to the 1990 US standard population to estimate
the age-adjusted prevalence, which was then projected
onto the 2001 US population estimates to calculate an
estimated age-adjusted prevalence in 2001 by stage of
disease.
RESULTS: The estimated year 2001 prevalence of col-
orectal cancer and median survival by AJCC stage were:
Stage I, n = 228,958, 9.7yrs.; Stage II, n = 223,936, 
6.7yrs.; Stage III, n = 145,307, 3.9yrs.; and Stage IV, 
n = 28,009, 0.8yrs.
CONCLUSION: Colorectal cancer in the US was found
to have decreasing prevalence and survival with increas-
ing clinical stage (severity).
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OBJECTIVE: When using non-patients as respondents 
in health state preference measurement, it is necessary 
to develop accurate descriptions of treatment alternatives
and health states patients may be likely to experience. We
developed descriptions of commonly used treatment
modalities for colorectal cancer (CRC) and ensuing health
states for use in subsequent preference measurement
studies.
METHODS: Following a literature review and clinical
expert input, we identiﬁed four commonly used treatment
modalities for CRC. Clinical data for each of the modal-
ities were abstracted from the literature, and reviewed by
